Fig. 4.
Terminal disease in NF-κB-deficient mice after PrPSc infection. A. Kaplan Meier survival curves of wild-type, NF-κB2- and Bcl-3-deficient mice. Bcl3–/–, Nfkb2–/– and C57Bl/6 mice as control were inoculated intracerebrally with 30 μl of 0.2% (w/v) RML6 brain homogenate, monitored daily for clinical symptoms and euthanized at the end-point of neurological disease. B. Mean of survival and SEM for all mice lines analysed are represented. Terminal disease stage is significantly reduced in NF-κB2-deficient (P = 0.01) and Bcl-3-deficient (P = 0.0001) mice compared with C57Bl/6 mice. NF-κB1-deficient mice showed no difference in the time-course of the disease compared with relevant heterozygous controls (P = 0.18). See Experimental procedures for detailed description of mice stains. Mice with p65 deletion in nestin expressing cells (p65flox/flox/NestinCre/wt) showed no difference in disease development compared with mice with intact p65 expression (p65flox/flox) (P = 0.285). Number of mice (n) and P-value are given.